Search results
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
20 maj 2016 · Described here are the preliminary antitumor effects of the RP2D in EGFR mutation-positive non-small cell lung cancer (NSCLC) previously treated with an EGFR TKI (most patients received ≥ 1 prior treatment) in 2 study populations: all subjects and subjects with T790M.
Methods: NSCLC patients previously treated with at least one EGFR-TKI were enrolled into the phase 1 part of this open-label Phase I/II study in Japan. ASP8273 was administered orally once daily (QD) and all patients were assessed for AEs, PK and preliminary anti-tumor activity.
14 gru 2017 · ASP8273 demonstrated antitumor activity in patients with EGFR-mutant lung cancers after prior treatment with EGFR TKIs. This study identified the ASP8273 RP2D to be 300 mg daily based on pharmacokinetics, pharmacodynamics, safety, and antitumor activity; the MTD was not established.
15 gru 2017 · ASP8273 is a third-generation EGFR TKI with antitumor activity in preclinical models of EGFR-mutant lung cancer that targets mutant EGFR, including EGFR T790M.
Conclusions: ASP8273 under MTD has demonstrated anti-tumor activity in NSCLC pts with tumors harboring both EGFR activating mutations and T790M resistance mutation. The phase 2 part of this study will further investigate the clinical activity of ASP8273 at the RP2D in pts with T790M.
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
